# Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread

> **NCT04631029** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 3 (actual)

## Conditions studied

- Extensive Stage Lung Small Cell Carcinoma
- Malignant Solid Neoplasm
- Metastatic Malignant Neoplasm in the Brain

## Interventions

- **BIOLOGICAL:** Atezolizumab
- **DRUG:** Carboplatin
- **DRUG:** Entinostat
- **DRUG:** Etoposide

## Key facts

- **NCT ID:** NCT04631029
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-27
- **Primary completion:** 2021-12-30
- **Final completion:** 2023-07-11
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2025-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04631029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04631029, "Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04631029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*